Raymond James Upgrades Fusion Pharmaceuticals to Strong Buy, Raises Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Rahul Sarugaser has upgraded Fusion Pharmaceuticals (NASDAQ:FUSN) from Outperform to Strong Buy and increased the price target from $12 to $15.
December 27, 2023 | 12:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Fusion Pharmaceuticals was upgraded by Raymond James from Outperform to Strong Buy, with a raised price target from $12 to $15.
Upgrades by analysts, especially to a Strong Buy rating, typically signal a positive outlook on the stock and can lead to increased investor confidence and a potential rise in the stock price in the short term. The increase in the price target further supports a bullish view on the stock.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100